The safety of long-acting ß2-agonists in the treatment of stable chronic obstructive pulmonary disease
Marc L Decramer,1 Nicola A Hanania,2 Jan O Lötvall,3 Barbara P Yawn41Respiratory Division, University Hospital, KU Leuven, Belgium; 2Section of Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, Houston, TX, USA; 3Krefting Research Centre, University of Gothenburg...
Main Authors: | Decramer ML, Hanania NA, Lötvall JO, Yawn BP |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-01-01
|
Series: | International Journal of COPD |
Online Access: | http://www.dovepress.com/the-safety-of-long-acting-szlig2-agonists-in-the-treatment-of-stable-c-a12070 |
Similar Items
-
Long-acting β2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety
by: Andrea Rossi, et al.
Published: (2008-07-01) -
GOLD in Practice: Chronic Obstructive Pulmonary Disease Treatment and Management in the Primary Care Setting
by: Yawn BP, et al.
Published: (2021-02-01) -
The effects of the presence of the corneal epithelium and supplemental hydrocortisone on ß-glucuronidase levels with corneal preservation
by: Mauger TF, et al.
Published: (2011-03-01) -
Management of patients during and after exacerbations of chronic obstructive pulmonary disease: the role of primary care physicians
by: Yawn BP, et al.
Published: (2011-09-01) -
Patient assessment of an electronic device for subcutaneous self-injection of interferon ß-1a for multiple sclerosis: an observational study in the UK and Ireland
by: D'Arcy C, et al.
Published: (2012-01-01)